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ABSTRACT: In this study, we apply a battery of molecular
similarity techniques to known inhibitors of kynurenine 3-
monooxygenase (KMO), querying each against a repository of
approved, experimental, nutraceutical, and illicit drugs. Four
compounds are assayed against KMO. Subsequently, diclofe-
nac (also known by the trade names Voltaren, Voltarol,
Aclonac, and Cataﬂam) has been conﬁrmed as a human KMO
protein binder and inhibitor in cell lysate with low micromolar
KD and IC50, respectively, and low millimolar cellular IC50. Hit
to drug hopping, as exempliﬁed here for one of the most successful anti-inﬂammatory medicines ever invented, holds great
promise for expansion into new disease areas and highlights the not-yet-fully-exploited potential of drug repurposing.
■ INTRODUCTION
Increasing costs1 and attrition rates2 associated with bringing a
new drug to market have driven interest in repurposing existing
drugs for new indications.3,4 Routine use of drugs “oﬀ-label” is
well-documented and most prevalent in pediatrics, with drugs
typically approved for use in adults being prescribed by
physicians for use in children.5,6 With the ability to use existing,
approved drugs “oﬀ-label”, the application of molecular
similarity techniques oﬀers an extremely attractive route toward
treating disease states, identifying approved drugs capable of
making similar interactions to known ligands of target proteins.
Kynurenine 3-monooxygenase (KMO) is a nicotinamide
adenine dinucleotide phosphate (NADPH)-dependent ﬂavo-
protein hydroxylase that catalyzes the hydroxylation of
kynurenine (L-Kyn) to generate cytotoxic 3-hydroxykynurenine
(3-HK).7,8 KMO has been identiﬁed as an important
therapeutic target in systemic inﬂammation triggered by acute
pancreatitis9,10 and in Huntington’s disease.11 KMO is a key
regulator of metabolic ﬂux through the kynurenine pathway of
tryptophan metabolism, the main route of tryptophan
metabolism in mammals.12 Perturbations in KMO activity,
using genetically altered mice deﬁcient in KMO12 and by
speciﬁc inhibitors,12,13 generate biologically important alter-
ations in plasma and tissue concentrations of several neuro-
active and immunoregulatory metabolites. KMO is found in
high concentrations in the liver and kidney and is also
expressed by macrophages and microglia cells.7 The protein is
localized on the mitochondrial outer membrane and contains a
stretch of hydrophobic amino acids at its C terminus, which is
believed to be the mitochondrial membrane-anchoring
domain.13 This transmembrane domain is thought to account
for the solubility diﬃculties encountered during the recombi-
nant protein production of the human enzyme.14 The crystal
structure of human KMO remains as-yet unsolved in the public
domain. Crystallization of membrane proteins is particularly
challenging because of the need for high yields of correctly
folded, homogeneous, stable protein.15 Importantly, detergent
is commonly required for the solubility and stability of
membrane proteins but is often detrimental to the success of
crystallization attempts.16 Approaches to tackle human KMO
inhibition using a Pseudomonas ﬂuorescens KMO crystal
structure have been successful,17,18 resulting in the exploration
of active compound series and progression to a clinical
candidate.19 In our study, we took a ligand-based20 approach,
applying molecular similarity techniques to rank approved and
experimental drugs in similarity to known KMO inhibitors.
■ RESULTS AND DISCUSSION
Ten small molecules known to be KMO inhibitors with
nanomolar- to low-micromolar-range half-maximal inhibitory
concentrations (IC50s) (Supporting Information Table S1)
were selected as input to molecular similarity techniques (see
Experimental Section). Small-molecule similars were extracted
from the DrugBank21 database. Nine of the actives were
deemed too dissimilar to anything in DrugBank to follow up
experimentally. One active compound, termed “Pharmacia
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WO199805660 core scaﬀold” displayed a high degree of
similarity to seven small molecules within DrugBank (Support-
ing Information Table S2). Patent literature documents
derivatives of the Pharmacia WO199805660 core scaﬀold as
having IC50s of less than 100 μM against Rattus norvegicus
KMO. Substructure searching of the ChEMBL database22
(version 23) revealed a series of 16 derivatives that have
activities on eight kinases based on an IC50 value cutoﬀ of 10
μM (see Supporting Information Table S3). However, no
targets for the unmodiﬁed Pharmacia WO199805660 core
scaﬀold are reported in ChEMBL. We were able to purchase
only four (Figure 1) of the seven priority molecules: quinaldic
acid, dipicolinic acid, sulfapyridine, and diclofenac. Quinaldic
acid is a product of L-Kyn catabolism via the kynurenic acid side
arm of the kynurenine pathway.23 Dipicolinic acid composes
5−15% of bacterial spores by weight and has been proposed as
a key component in their heat stress pathways.24 Sulfapyridine,
an antibacterial classically used to treat pneumonia and widely
used during the Second World War, is now no longer widely
prescribed because of the problems with crystallization in the
bladder. Finally, diclofenac, a nanomolar inhibitor of cyclo-
oxygenases, is a widely used nonsteroidal anti-inﬂammatory25
used to treat inﬂammation and pain in both humans and
animals.
The four commercially available compounds were assayed in
our KMO lysate enzymatic inhibition assay.26 Only diclofenac
was shown to have inhibitory properties against the KMO
enzyme, achieving a 38% inhibition at a diclofenac concen-
tration of 10 μM. Enzymatic testing revealed an IC50 of 13.6 ±
1.34 μM for diclofenac against KMO in the cell lysate and 1.35
± 0.10 mM against whole cells, as shown by the dose−response
curves in Figure 2. Our microdialysis binding assay27
demonstrated a KD of 64.84 ± 29.47 μM for the interaction
and direct binding of diclofenac to KMO (Table 1).
After the conﬁrmation of diclofenac as a binder and inhibitor
of KMO, ﬁve Saccharomyces cerevisiae KMO crystal structures
were published by Amaral et al.28 Of key interest to the
evaluation of diclofenac as a KMO inhibitor are two of these
structures: ﬁrst, PDB ID 4J36 containing KMO, a ﬂavin−
adenine dinucleotide (FAD) molecule, and a small-molecule
inhibitor and second UPF 648, a 2-(3,4-dichlorobenzoyl)-
cyclopropanecarboxylic acid, displaying a Ki of 74 ± 14 nM
against yeast KMO and 56.7 ± 6.8 nM against human KMO.
Another structure with PDB ID 4J33 contains S. cerevisiae
KMO bound to only the FAD molecule, allowing a valuable
comparison of conformational changes upon inhibitor binding.
Amaral et al. suggest, through the use of model building, that
UPF 648 acts as a mimic of L-Kyn, binding into the same
pocket, blocking L-Kyn turnover via NADPH into 3-HK.
However, UPF 648 is larger than L-Kyn, with a molecular
weight of 259 versus 208, and has a signiﬁcantly more
hydrophobic bulk (clog P values of 2.27 and −1.3,
respectively). This is structurally accounted for by loop
movement (Pro321−Gln325) and reorientation of a six-
stranded antiparallel β-sheet. Amaral asserts the validity for
the use of S. cerevisiae KMO as a template for a structure-based
drug design against human KMO. In addition, the nonhuman
structure of P. ﬂuorescens KMO has been used to develop
compounds with nanomolar IC50s
18 as well as a clinical
candidate.19 Visual overlays of UPF 648 and diclofenac show a
striking similarity, suggesting a common binding mode. Indeed,
docking of diclofenac into the S. cerevisiae KMO structure with
PDB ID 4J36 using Autodock Vina 1.1.2 (see Figure 3 and
Supporting Information for docking protocol) reveals a
plausible binding mode.
Figure 1. Molecular similarity to the Pharmacia WO199805660 core
scaﬀold led to four compounds being sourced for testing. Only
diclofenac was identiﬁed as an active inhibitor of KMO.
Figure 2. Plot showing the inhibition of KMO by diclofenac in whole
cells and in the cell lysate-based assays.
Table 1. Summary of Diclofenac vs KMO Inhibition in the
Enzymatic and Microdialysis Assays
assay protein source protein/assay parameter value
kinetic HEK-KMO cell
lysate
200 μG of total
protein
IC50 13.6 μM
kinetic HEK-KMO
whole cells
20 000 cells IC50 1.35 mM
microdialysis enriched
HEK-KMO
lysate
10 μM KMO
protein
KD 64.8 μM
Figure 3. Saccharomyces cerevisiae KMO (green) from the structure
with PDB ID 4J36 in the complex with the FAD cofactor (magenta)
and UPF 648 (blue). Predicted binding mode of diclofenac (cyan) is
shown in the overlay.
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■ CONCLUSION
In conclusion, we have successfully applied molecular similarity
methods to identify diclofenac, an approved and widely used
drug, as capable of binding to, and inhibiting, human KMO
with a limited low micromolar aﬃnity and activity in vitro and
in cell lysate. Because of the diﬃculty in purifying full-length
human KMO, the binding aﬃnity is possibly underestimated
and might be closer to the lysate-derived IC50 value, with both
results representing good estimates. The considerable potency
reduction of ∼1 log step of diclofenac in cells is likely due to
the impaired cellular permeability associated with the carboxylic
acid moiety. Additionally, diclofenac is known to bind to and
inhibit many extra- and intracellular targets. Interestingly, none
of the eight kinases reported as targets for the Pharmacia core
scaﬀold are shared with diclofenac. The ChEMBL database
(version 23) reports single-digit nanomolar IC50s/KDs for three
protein targetscyclooxygenase 1 and 2 and the interleukin-8
receptor A. See Supporting Information Table S4 for
ChEMBL-assigned targets of diclofenac. Depending on the
abundance and aﬃnities of the high number of known targets
for diclofenac, the eﬀective concentration exposed to intra-
cellular KMO may be greatly reduced. It is important to
emphasize that the presented results only highlight a starting
point for a possible drug repurposing process. However, the
data serve to highlight the power of molecular similarity
techniques and their value in the discovery of medicinal
chemistry starting points and the prediction of oﬀ-target eﬀects.
Intensive work combining structural biology and several rounds
of medicinal chemistry would be needed to identify a diclofenac
derivative with nanomolar activity to reach a lead compound
status for KMO.
■ EXPERIMENTAL SECTION
Molecular Similarity. A survey of literature followed by
visual inspection and clustering identiﬁed 10 potent KMO
inhibitors (Supporting Information Table S1) that had their
predicted lowest energy three-dimensional (3D) conformation
generated using Omega229 (OpenEye Scientiﬁc, version 2.3.2)
and written out in the SD ﬁle format. A data set containing
approved, experimental, nutraceutical, illicit, and withdrawn
drugs was obtained from the DrugBank21 Web service (data
downloaded on 30/6/2010), and the same 3D conformer
generation procedure was applied with the addition of a salt-
stripping step using OpenBabel30 (version 2.2.2), generating
4648 low-energy conformers. Programs implementing MACCS,
Path, and LINGO ﬁngerprints were implemented in the Java
programming language using the Chemistry Development
Kit.31 C++ programs were written making use of the
OpenBabel API30 to generate FP2, FP3, and FP4 ﬁngerprints.
Implementations of USR32 and UFSRAT33 were also written in
C++. Tanimoto distances34 were used to score molecules by
ﬁngerprint-based methods (FP2, FP3, FP4, Path, LINGO, and
MACCS). A simple Euclidean distance was used for USR and
UFSRAT similarity comparison scoring. Each of the 10 known
KMO inhibitors was then scored against each of the 4648 drug
data set using each of the 8 measures of molecular similarity,
resulting in a total of 371 840 similarity comparisons (see
Supporting Information spreadsheet). Each similarity method
run on a known inhibitor was then sorted in the order of
descending level of calculated similarity. See Supporting
Information for full results. Manual inspection of results
revealed that only the UFSRAT similarity method applied to
the Pharmacia WO199805660 core scaﬀold gave rise to
convincing similars. Seven of these similars were prioritized,
but only four were available for purchase and subsequent assay.
Cloning of full-length human KMO (KMO (V5-6His)
construct), expression of this construct in HEK293 cells, and
analysis of KMO enzymatic activity using liquid chromatog-
raphy−mass spectrometry (LC−MS) were performed, as
described by us previously.10
Compound IC50 Determination in the KMO Lysate. To
determine the IC50 of compounds against human KMO
enzyme in the cell lysate,10 the compounds were incubated in
duplicate at the following concentrations: 200, 100, 50, 20, 10,
1, 0.5, 0.2, and 0.1 μM. The low control for this assay consisted
of 200 μg of cell lysate (total protein) in the absence of an
inhibitor, whereas high controls were enzyme-free.
IC50 data were plotted using the GraFit v5.0.1 software
(Erithacus Software Limited). The standard IC50 equation in
GraFit, =
+ × | |
y 100
1 e s
x( ln IC50
) , was used to ﬁt the data to obtain IC50
and the Hill slope value s. Input parameters were percentage of
inhibition (y) and logarithm of compound concentration (x).
Cellular Compound IC50 Determination. The IC50 values
of compounds were tested in the cellular context to determine
the cell permeability of test compounds. HEK293-KMO(V5-
6His) cells were passaged in 96-well plates at 2 × 104 cells per
well in Dulbecco’s modiﬁed Eagle’s medium with 10% fetal
bovine serum, 1% L-glutamine, and 1% penicillin−streptomy-
cin. The cells were incubated overnight at 37 °C in 5% CO2/
95% O2. The assay medium utilized was opti-MEM containing
1% L-glutamine, 1% penicillin−streptomycin, and 200 μM L-
Kyn. The compounds for testing were diluted in this medium
with a ﬁnal dimethyl sulfoxide (DMSO) concentration of 1%.
3-HK was diluted in the assay medium in the absence of L-Kyn
to produce a standard curve with the following concentrations:
200, 100, 50, 20, 10, 1, 0.5, 0.2, and 0.1 μM. Low controls
consisted of opti-MEM with 1% L-glutamine, 1% penicillin−
streptomycin, 200 μM L-Kyn, and 1% DMSO, whereas high
controls consisted of the same buﬀer minus L-Kyn. The
standards, compounds, and control dilutions were added to the
cells over 20 h at 37 °C in 5% CO2/95% O2. Following
incubation, the assay samples (i.e., cellular supernatants) were
transferred to a 96-well masterblock before the addition of 500
μL of acetonitrile containing 25 μg/mL d5-tryptophan per well
to terminate activity. This solution was dried under nitrogen,
and each sample was solubilized by the addition of 100 μL of
30:70 methanol/water with 0.1% formic acid. The samples
were transferred to 96-well v-bottom plates for MS analysis.
(MS analysis was performed as described above.)
Microdialysis. Microdialysis was used to assess the direct
binding aﬃnity, expressed as dissociation constant, KD, of
diclofenac for KMO in a method similar to that reported by
Weidemann et al.27 KMO (expressed as above) was enriched
by NiNTA aﬃnity chromatography. RED (rapid equilibrium
dialysis) device inserts (molecular weight cutoﬀ 8 kDa) were
placed in the wells of a compatible base plate (Piece, Thermo
Scientiﬁc). The enriched KMO target protein was diluted to a
concentration of 10 μM in the assay buﬀer [20 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid pH 7.0] in a
total volume of 100 μL and added to the sample chamber of the
RED device insert. Assay buﬀer (300 μL) was added to the
dialysis chamber of the RED device insert. The compound was
added to the starter volume of the sample chamber at a ﬁnal
concentration of 20 μM. Controls consisted of compounds at
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the same concentration in the assay buﬀer in the absence of the
enzyme. The plate was covered with a sealing tape and
incubated for 6 h at 37 °C with rotation at 100 rpm. Samples of
50 μL were obtained from both the sample and dialysis
compartments of the chamber and transferred to LC−MS vials
with 10 μL of acetonitrile per sample for MS analysis (see
Supporting Information). KD values were calculated using the
data obtained from MS analysis according to the formula
determined by Weidemann et al.27 Diclofenac was diluted in
the assay buﬀer at the concentrations of 1, 2, 5, 10, 20, and 50
μM in LC−MS vials to provide a standard curve, allowing
quantiﬁcation of concentrations from the assay samples. The
samples were analyzed using the MS method previously
described.35
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